Urwyler, Pascal
Abu Hussein, Nebal
Bridevaux, Pierre O.
Chhajed, Prashant N.
Geiser, Thomas
Grendelmeier, Peter
Joos Zellweger, Ladina
Kohler, Malcolm
Maier, Sabrina
Miedinger, David
Tamm, Michael
Thurnheer, Robert
Dieterle, Thomas
Leuppi, Joerg D.
Funding for this research was provided by:
Novartis (NA)
Boehringer Ingelheim (NA)
Article History
Received: 17 September 2018
Accepted: 27 November 2018
First Online: 5 February 2019
Ethics approval and consent to participate
: We received ethical approval for this study by the local ethical committee (Ethikkommission Nordwest- und Zentralschweiz (EKNZ), formerly Ethikkommission beider Basel (EKBB)) in 2006 (EK Nr. 170/06) and subsequently by ethical committees of all other participating Swiss cantons. The study was also registered on ClinicalTrials.gov (NCT02065921).
: Not applicable.
: The authors declare that they have no competing interests in relation to the work described.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.